now building

Houston park breaks ground on innovative land bridge

The new Land Bridge will create safe passage from humans and animals. Rendering courtesy of Nelson Byrd Woltz

Last week, Memorial Park made headlines when it triumphantly opened its lush and verdant Eastern Glades. The 100-acre destination transformed largely inaccessible green space into a destination offering up picnic areas, native wetlands, a savanna, a pine-hardwood forest, green spaces, and miles of accessible trails.

Now, the Memorial Park Conservancy has announced that construction has begun on Memorial Park's Land Bridge and Prairie project. The 100-acre project, slated for completion in late 2022, will create a new community space with enhanced recreation opportunities for park users with "unmatched vantage points of urban skyline views," according to a press release. Memorial Park's prairie, which adjoins the Land Bridge to the north and the south, aims to re-establish endangered native Gulf Coast prairie, savanna, and wetlands.

The Land Bridge and its corresponding prairie are part of the Memorial Park Master Plan, made possible by a $70 million gift from the Kinder Foundation, and associated the Ten-Year Plan.

Commuters, no need to worry: Memorial Drive will remain open throughout the duration of Land Bridge and Prairie construction. Traffic will be reduced from three lanes to two each way beginning September, while a new section of Memorial Drive and the tunnel arch structures for the Land Bridge are completed directly south of the operating lanes.
All lanes will reopen in fall 2021 once the new Memorial Drive alignment through tunnels is complete, according to a release.

The Land Bridge Photo courtesy of MPC

Additionally, per the conservancy, the Land Bridge will:


Provide safety and connectivity
This will benefit both humans and animals crossing Memorial Drive. The Land Bridge will establish two dynamic greenspace connections over Memorial Drive that reunite the north and south sides of the Park while expanding the existing trail network and providing increased connectivity within the Park. While the Land Bridge will provide connectivity for Park visitors and wildlife over Memorial Drive, a stream corridor constructed through the Prairie and a culvert will provide connectivity under Memorial Drive. Together these elements will provide much-needed wildlife connectivity within Houston's largest urban wilderness park and to the natural Buffalo Bayou corridor.

Restore nearly 45 acres of native coastal prairie
This will establish a more resilient ecology during natural disruptions and improve animal habitats. Native coastal prairie is one of the most endangered ecosystems in North America, with less than 1 percent of its historic range remaining today. These forthcoming ecosystems will be home to numerous species of flora and fauna.

Create a new destination for visitors
New opportunities include nature education, leisure walking, interval running and cycling, stargazing, relaxing, and more.

Improve stormwater management
The project will detain stormwater that flows through Memorial Park to Buffalo Bayou during heavy rain events, lessening the impact of peak storms. A stream channel constructed through the site, along with the network of native prairie and savanna, will support greater regional biodiversity and act as a green sponge, helping to absorb and clean stormwater. The constructed wetlands will help to purify water and reduce roadway pollutants that would otherwise be released into the watershed.

"From aiding with critical stormwater management to granting people and wildlife safer crossing over Memorial Drive to providing a dynamic outdoor destination for all visitors, the Land Bridge and Prairie will be an asset not just for Memorial Park but for all Houstonians," said Mayor Sylvester Turner in a statement. "It's about unifying both sides of the Park and giving people a new landmark that they can be proud of and use to enjoy nature."

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News